Athira Pharma (ATHA) Insider Trading & Ownership $0.65 +0.01 (+1.57%) (As of 11/19/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Athira Pharma (NASDAQ:ATHA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage19.80%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$563,684.04Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$29,592.93 Get ATHA Insider Trade Alerts Want to know when executives and insiders are buying or selling Athira Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ATHA Insider Buying and Selling by Quarter Ad True Gold RepublicCentral Bank Abandons USDExperts suggest we're on the brink of a major economic shift. Gold's value could soar when Trump brings back the gold standard Click here to download your copy of our Gold Standard Guide now, before Trump's policies start impac Athira Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/5/2024Andrew GengosCFOSell1,272$0.57$725.04 9/5/2024Mark James LittonCEOSell5,032$0.57$2,868.24 9/5/2024Rachel LeningtonCOOSell2,525$0.57$1,439.25 6/24/2024Kelly A RomanoDirectorBuy27,400$2.42$66,308.00 6/21/2024Kelly A RomanoDirectorBuy15,000$2.26$33,900.00 1/5/2024Andrew GengosInsiderSell1,208$2.91$3,515.28 Central Bank Abandons USD (Ad)Experts suggest we're on the brink of a major economic shift. Gold's value could soar when Trump brings back the gold standard Click here to download your copy of our Gold Standard Guide now, before Trump's policies start impac1/5/2024Mark James LittonCEOSell4,820$2.91$14,026.20 1/5/2024Mark WorthingtonGeneral CounselSell2,412$2.91$7,018.92 12/29/2023Perceptive Advisors LlcDirectorBuy163,954$2.38$390,210.52 12/27/2023Perceptive Advisors LlcDirectorBuy32,134$2.28$73,265.52 (Data available from 1/1/2013 forward) ATHA Insider Trading Activity - Frequently Asked Questions Who is on Athira Pharma's Insider Roster? The list of insiders at Athira Pharma includes Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc, and Rachel Lenington. Learn more on insiders at ATHA. What percentage of Athira Pharma stock is owned by insiders? 19.80% of Athira Pharma stock is owned by insiders. Learn more on ATHA's insider holdings. Which Athira Pharma insiders have been buying company stock? The following insiders have purchased ATHA shares in the last 24 months: Andrew Gengos ($242,883.84), Glenna Mileson ($142,500.00), James A Johnson ($12,000.00), Kelly A Romano ($198,908.00), and Perceptive Advisors Llc ($463,476.04). How much insider buying is happening at Athira Pharma? Insiders have purchased a total of 403,500 ATHA shares in the last 24 months for a total of $1,059,767.88 bought. Which Athira Pharma insiders have been selling company stock? The following insiders have sold ATHA shares in the last 24 months: Andrew Gengos ($4,240.32), Mark James Litton ($16,894.44), Mark Worthington ($7,018.92), and Rachel Lenington ($1,439.25). How much insider selling is happening at Athira Pharma? Insiders have sold a total of 17,269 Athira Pharma shares in the last 24 months for a total of $29,592.93 sold. Athira Pharma Key ExecutivesDr. Mark J. Litton M.B.A. (Age 56)Ph.D., President, CEO & Director Compensation: $882.7kMr. Andrew W. Gengos (Age 60)CFO & Chief Business Officer Compensation: $396.16k1 recent tradesMs. Rachel P. Lenington M.B.A. (Age 51)Chief Development Officer & COO Compensation: $578kDr. Kevin Church Ph.D. (Age 39)Chief Scientific Officer Compensation: $123.67kMs. Julie RathbunHead of Investor RelationsMr. Mark F. Worthington J.D. (Age 58)General Counsel & Corporate Secretary Compensation: $503.83kMs. Samantha WillingChief People OfficerDr. Javier San Martin M.D. (Age 59)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies PASG Insider Trading ALGS Insider Trading AGEN Insider Trading ANRO Insider Trading COYA Insider Trading ELYM Insider Trading IPSC Insider Trading IVVD Insider Trading ME Insider Trading BNTC Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:ATHA) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredCentral Bank Abandons USDExperts suggest we're on the brink of a major economic shift. Gold's value could soar when Trump brings bac...True Gold Republic | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHA Stock Alerts